A newly approved pancreatic cancer pill halted tumor growth in 9 out of 10 patients when paired with chemo

by Adrienne Erin

Pancreatic cancer is one of the deadliest cancers, and treatment options have barely changed in decades. Now a daily pill that targets the gene mutation behind most pancreatic cancers is showing striking results. In an early trial, combining the pill with chemotherapy stopped tumors from growing in 9 out of 10 patients whose cancer had spread, and in about 1 in 12, scans showed no detectable cancer. Cancer Research UK called it “the biggest leap forward in decades.”

Key Takeaways

  • The drug, daraxonrasib, is a daily pill that blocks RAS, a family of proteins that drive the growth of most pancreatic cancers.
  • In a phase 1/2 trial of 61 people with metastatic pancreatic cancer, daraxonrasib plus chemotherapy stopped tumor growth in 90% of patients.
  • Just over 60% saw their tumors shrink or disappear, and about 8% had no detectable cancer on scans.
  • The results were presented on November 20, 2026, at a major European cancer research symposium. They haven’t yet been published in a peer-reviewed journal.
  • Daraxonrasib was approved by the FDA in 2026 on its own for people whose cancer has spread and progressed after earlier treatment. Its use with chemotherapy as a first treatment is still being studied.

What the new trial found

Researchers tested daraxonrasib combined with chemotherapy in 61 people whose pancreatic cancer had spread to other parts of the body. Patients were followed for an average of 18 months.

The results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics:

  • 90% of patients: Their tumors stopped growing.
  • Just over 60%: Their tumors shrank or disappeared.
  • About 8%, or 1 in 12: Scans showed no detectable cancer.

Some patients had not seen their cancer return during follow-up. A researcher from Memorial Sloan Kettering Cancer Center said the combination produced deeper responses and nearly doubled the time the disease was kept under control, which could eventually lead to longer survival.

Why this drug is different

More than 90% of pancreatic cancers are driven by mutations in a gene called KRAS. For decades, KRAS was considered “undruggable” because the protein it makes has no obvious place for a drug to attach.

Daraxonrasib, made by Revolution Medicines, works differently from earlier drugs that target only one specific KRAS mutation. It blocks the active “on” form of several RAS proteins, so it can work against many different mutations.

The drug is already approved in the U.S.

In August 2026, the FDA approved daraxonrasib for adults with metastatic pancreatic cancer who have already had at least one treatment, or who can’t have intensive chemotherapy.

The approval was based on a large phase 3 trial of 500 patients, which compared daraxonrasib alone with chemotherapy as a second treatment:

  • Median survival: 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy
  • Time before the cancer worsened: 7.2 months, compared with 3.6 months
  • Tumor shrinkage: About 32% of patients, compared with about 11%

The most common side effects were rash, mouth sores, nausea and diarrhea.

The new trial tests whether giving daraxonrasib together with chemotherapy, earlier in treatment, can work even better.

What the new results can’t tell us yet

  • The trial was small, with 61 patients, and had no comparison group.
  • Results haven’t been published in a peer-reviewed journal yet.
  • “No detectable cancer” isn’t a cure. Cancer can return even when scans show no signs of it, and longer follow-up is needed.
  • Survival data for the combination isn’t available yet. Larger trials are underway.

Why this matters

Pancreatic cancer is often found late, when it has already spread, because early symptoms are vague. Only about 13% of people survive five years after diagnosis. It’s expected to cause about 53,000 deaths a year in the U.S.

Warning signs to know

Pancreatic cancer often doesn’t cause symptoms until it’s advanced. See a doctor if you notice:

  • Yellowing of the skin or eyes (jaundice), dark urine or pale stools
  • Pain in the upper abdomen that spreads to the back
  • Unexplained weight loss or loss of appetite
  • New-onset diabetes, especially after age 50 and without weight gain
  • Ongoing nausea, bloating or greasy, floating stools

If you have a family history of pancreatic cancer or inherited mutations such as BRCA2, ask your doctor whether genetic counseling or screening is right for you.

If you or a loved one has pancreatic cancer, ask your oncologist about genetic testing of the tumor, whether daraxonrasib may be an option, and whether a clinical trial could be right for you.

This isn’t a substitute for medical advice. Talk to your doctor about treatment options.


Sources:

Pancreatic cancer is one of the deadliest cancers, and treatment options have barely changed in decades. Now a daily pill that targets the gene mutation behind most pancreatic cancers is showing striking results. In an early trial, combining the pill with chemotherapy stopped tumors from growing in 9 out of 10 patients whose cancer had spread, and in about 1 in 12, scans showed no detectable cancer. Cancer Research UK called it “the biggest leap forward in decades.”

Key Takeaways

  • The drug, daraxonrasib, is a daily pill that blocks RAS, a family of proteins that drive the growth of most pancreatic cancers.
  • In a phase 1/2 trial of 61 people with metastatic pancreatic cancer, daraxonrasib plus chemotherapy stopped tumor growth in 90% of patients.
  • Just over 60% saw their tumors shrink or disappear, and about 8% had no detectable cancer on scans.
  • The results were presented on November 20, 2026, at a major European cancer research symposium. They haven’t yet been published in a peer-reviewed journal.
  • Daraxonrasib was approved by the FDA in 2026 on its own for people whose cancer has spread and progressed after earlier treatment. Its use with chemotherapy as a first treatment is still being studied.

What the new trial found

Researchers tested daraxonrasib combined with chemotherapy in 61 people whose pancreatic cancer had spread to other parts of the body. Patients were followed for an average of 18 months.

The results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics:

  • 90% of patients: Their tumors stopped growing.
  • Just over 60%: Their tumors shrank or disappeared.
  • About 8%, or 1 in 12: Scans showed no detectable cancer.

Some patients had not seen their cancer return during follow-up. A researcher from Memorial Sloan Kettering Cancer Center said the combination produced deeper responses and nearly doubled the time the disease was kept under control, which could eventually lead to longer survival.

Why this drug is different

More than 90% of pancreatic cancers are driven by mutations in a gene called KRAS. For decades, KRAS was considered “undruggable” because the protein it makes has no obvious place for a drug to attach.

Daraxonrasib, made by Revolution Medicines, works differently from earlier drugs that target only one specific KRAS mutation. It blocks the active “on” form of several RAS proteins, so it can work against many different mutations.

The drug is already approved in the U.S.

In August 2026, the FDA approved daraxonrasib for adults with metastatic pancreatic cancer who have already had at least one treatment, or who can’t have intensive chemotherapy.

The approval was based on a large phase 3 trial of 500 patients, which compared daraxonrasib alone with chemotherapy as a second treatment:

  • Median survival: 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy
  • Time before the cancer worsened: 7.2 months, compared with 3.6 months
  • Tumor shrinkage: About 32% of patients, compared with about 11%

The most common side effects were rash, mouth sores, nausea and diarrhea.

The new trial tests whether giving daraxonrasib together with chemotherapy, earlier in treatment, can work even better.

What the new results can’t tell us yet

  • The trial was small, with 61 patients, and had no comparison group.
  • Results haven’t been published in a peer-reviewed journal yet.
  • “No detectable cancer” isn’t a cure. Cancer can return even when scans show no signs of it, and longer follow-up is needed.
  • Survival data for the combination isn’t available yet. Larger trials are underway.

Why this matters

Pancreatic cancer is often found late, when it has already spread, because early symptoms are vague. Only about 13% of people survive five years after diagnosis. It’s expected to cause about 53,000 deaths a year in the U.S.

Warning signs to know

Pancreatic cancer often doesn’t cause symptoms until it’s advanced. See a doctor if you notice:

  • Yellowing of the skin or eyes (jaundice), dark urine or pale stools
  • Pain in the upper abdomen that spreads to the back
  • Unexplained weight loss or loss of appetite
  • New-onset diabetes, especially after age 50 and without weight gain
  • Ongoing nausea, bloating or greasy, floating stools

If you have a family history of pancreatic cancer or inherited mutations such as BRCA2, ask your doctor whether genetic counseling or screening is right for you.

If you or a loved one has pancreatic cancer, ask your oncologist about genetic testing of the tumor, whether daraxonrasib may be an option, and whether a clinical trial could be right for you.

This isn’t a substitute for medical advice. Talk to your doctor about treatment options.


Sources:

Adrienne Erin

Adrienne holds a Bachelor of Science in Kinesiology, where she developed a strong foundation in exercise physiology and human nutrition. Before joining DailyHealthPost, she spent several years writing about health and wellness topics, translating nutrition and fitness research into practical guidance for everyday readers.

Advertisement